SAB Biotherapeutics (NASDAQ:SABS) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of SAB Biotherapeutics (NASDAQ:SABS) from a strong sell rating to a sell rating in a research note issued to investors on Saturday.

Several other brokerages have also recently commented on SABS. Jefferies Financial Group initiated coverage on SAB Biotherapeutics in a research report on Wednesday, May 20th. They issued a “buy” rating and a $11.00 target price for the company. Chardan Capital boosted their price target on shares of SAB Biotherapeutics from $14.00 to $16.00 and gave the company a “buy” rating in a report on Wednesday, June 17th. Leerink Partners increased their price objective on shares of SAB Biotherapeutics from $7.00 to $12.00 and gave the company an “outperform” rating in a research note on Monday, June 15th. Barclays began coverage on shares of SAB Biotherapeutics in a report on Wednesday, June 24th. They set an “overweight” rating and a $13.00 price objective for the company. Finally, Rodman & Renshaw reaffirmed a “buy” rating and set a $13.00 price objective on shares of SAB Biotherapeutics in a report on Monday, May 11th. Nine equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $12.00.

SAB Biotherapeutics Stock Performance

NASDAQ SABS opened at $3.44 on Friday. The company’s fifty day moving average is $3.69 and its two-hundred day moving average is $3.84. SAB Biotherapeutics has a 52-week low of $1.85 and a 52-week high of $5.15. The company has a debt-to-equity ratio of 0.01, a current ratio of 11.45 and a quick ratio of 11.45. The firm has a market capitalization of $263.02 million, a price-to-earnings ratio of -1.63 and a beta of 0.52.

SAB Biotherapeutics (NASDAQ:SABS) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.15). Equities research analysts forecast that SAB Biotherapeutics will post -1.19 EPS for the current year.

Institutional Investors Weigh In On SAB Biotherapeutics

Large investors have recently made changes to their positions in the company. PNC Financial Services Group Inc. acquired a new stake in shares of SAB Biotherapeutics during the 1st quarter worth about $29,000. ADAR1 Capital Management LLC acquired a new position in SAB Biotherapeutics in the third quarter valued at about $30,000. Dimensional Fund Advisors LP acquired a new position in SAB Biotherapeutics in the third quarter valued at about $32,000. State of Wyoming bought a new stake in SAB Biotherapeutics during the fourth quarter worth about $34,000. Finally, Virtu Financial LLC bought a new stake in SAB Biotherapeutics during the third quarter worth about $40,000. Institutional investors own 7.82% of the company’s stock.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.